KR101457966B1 - Ｐｇｄｓ 억제제로서 피리미딘 아미드 화합물 - Google Patents
Ｐｇｄｓ 억제제로서 피리미딘 아미드 화합물 Download PDFInfo
- Publication number
- KR101457966B1 KR101457966B1 KR1020087008306A KR20087008306A KR101457966B1 KR 101457966 B1 KR101457966 B1 KR 101457966B1 KR 1020087008306 A KR1020087008306 A KR 1020087008306A KR 20087008306 A KR20087008306 A KR 20087008306A KR 101457966 B1 KR101457966 B1 KR 101457966B1
- Authority
- KR
- South Korea
- Prior art keywords
- phenyl
- carboxylic acid
- pyrimidine
- fluoro
- benzylamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- VPCYLYXVMCYJRA-UHFFFAOYSA-N CC(C)S(NCc1cc(CNC(c2cnc(C(CC=C3)C=C3F)nc2)=O)ccc1)(=O)=O Chemical compound CC(C)S(NCc1cc(CNC(c2cnc(C(CC=C3)C=C3F)nc2)=O)ccc1)(=O)=O VPCYLYXVMCYJRA-UHFFFAOYSA-N 0.000 description 1
- BOMXTZVSPATBSA-UHFFFAOYSA-N CNS(c1cc(CNC(c2cnc(-c3ccccc3)nc2)=O)ccc1)(=O)=O Chemical compound CNS(c1cc(CNC(c2cnc(-c3ccccc3)nc2)=O)ccc1)(=O)=O BOMXTZVSPATBSA-UHFFFAOYSA-N 0.000 description 1
- TUCVEEYRMALHSH-UHFFFAOYSA-N CNS(c1cc(CNC(c2cnc(-c3cccnc3)nc2)=O)ccc1)(=O)=O Chemical compound CNS(c1cc(CNC(c2cnc(-c3cccnc3)nc2)=O)ccc1)(=O)=O TUCVEEYRMALHSH-UHFFFAOYSA-N 0.000 description 1
- VTYVJBLNCPQAMD-UHFFFAOYSA-N CS(N1CC(CNC(c2cnc(-c3cccc(F)c3)nc2)=O)CCC1)(=O)=O Chemical compound CS(N1CC(CNC(c2cnc(-c3cccc(F)c3)nc2)=O)CCC1)(=O)=O VTYVJBLNCPQAMD-UHFFFAOYSA-N 0.000 description 1
- YZOXHJBEEVTLHI-UHFFFAOYSA-N CS(Nc1cc(CNC(c2cnc(-c3cc(F)ccc3)nc2)=O)ccn1)(=O)=O Chemical compound CS(Nc1cc(CNC(c2cnc(-c3cc(F)ccc3)nc2)=O)ccn1)(=O)=O YZOXHJBEEVTLHI-UHFFFAOYSA-N 0.000 description 1
- FJWQNQUVPUIMSK-UHFFFAOYSA-N NS(c1ccc(CCNC(c2cnc(-c3ccccc3)nc2)=O)cc1)(=O)=O Chemical compound NS(c1ccc(CCNC(c2cnc(-c3ccccc3)nc2)=O)cc1)(=O)=O FJWQNQUVPUIMSK-UHFFFAOYSA-N 0.000 description 1
- KNHCIMSILBLYJD-UHFFFAOYSA-N O=C(c1cnc(-c2ccccc2)nc1)NCCN(CCN1)C1=O Chemical compound O=C(c1cnc(-c2ccccc2)nc1)NCCN(CCN1)C1=O KNHCIMSILBLYJD-UHFFFAOYSA-N 0.000 description 1
- HLBSKPXCRHCMRC-UHFFFAOYSA-N O=C(c1cnc(-c2ccccc2)nc1)NCc(cc1)ccc1S(N1CCOCC1)(=O)=O Chemical compound O=C(c1cnc(-c2ccccc2)nc1)NCc(cc1)ccc1S(N1CCOCC1)(=O)=O HLBSKPXCRHCMRC-UHFFFAOYSA-N 0.000 description 1
- HNIGPKKUKAPUOL-UHFFFAOYSA-N O=C(c1cnc(-c2cccnc2)nc1)Nc1ccccc1 Chemical compound O=C(c1cnc(-c2cccnc2)nc1)Nc1ccccc1 HNIGPKKUKAPUOL-UHFFFAOYSA-N 0.000 description 1
- CGJXBDISGFTPNS-UHFFFAOYSA-N OCCCNS(c1cc(CNC(c2cnc(-c3cccc(F)c3)nc2)=O)ccc1)(=O)=O Chemical compound OCCCNS(c1cc(CNC(c2cnc(-c3cccc(F)c3)nc2)=O)ccc1)(=O)=O CGJXBDISGFTPNS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72357005P | 2005-10-04 | 2005-10-04 | |
| US60/723,570 | 2005-10-04 | ||
| PCT/US2006/038841 WO2007041634A1 (en) | 2005-10-04 | 2006-10-04 | Pyrimidine amide compounds as pgds inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20080050611A KR20080050611A (ko) | 2008-06-09 |
| KR101457966B1 true KR101457966B1 (ko) | 2014-11-04 |
Family
ID=37635758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020087008306A Expired - Fee Related KR101457966B1 (ko) | 2005-10-04 | 2006-10-04 | Ｐｇｄｓ 억제제로서 피리미딘 아미드 화합물 |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US8202863B2 (enExample) |
| EP (1) | EP1937652B1 (enExample) |
| JP (1) | JP5452925B2 (enExample) |
| KR (1) | KR101457966B1 (enExample) |
| CN (2) | CN101538246B (enExample) |
| AR (1) | AR056871A1 (enExample) |
| AU (1) | AU2006299428B2 (enExample) |
| BR (1) | BRPI0616815A2 (enExample) |
| CA (1) | CA2624749C (enExample) |
| CR (1) | CR9832A (enExample) |
| DO (1) | DOP2006000210A (enExample) |
| EC (1) | ECSP088335A (enExample) |
| ES (1) | ES2514471T3 (enExample) |
| IL (1) | IL190411A (enExample) |
| MA (1) | MA29925B1 (enExample) |
| MY (1) | MY151172A (enExample) |
| NO (1) | NO20082000L (enExample) |
| NZ (1) | NZ567208A (enExample) |
| PE (2) | PE20110118A1 (enExample) |
| RU (1) | RU2420519C2 (enExample) |
| SG (1) | SG166121A1 (enExample) |
| TN (1) | TNSN08104A1 (enExample) |
| TW (1) | TWI415839B (enExample) |
| UA (1) | UA93213C2 (enExample) |
| UY (1) | UY29840A1 (enExample) |
| WO (1) | WO2007041634A1 (enExample) |
| ZA (1) | ZA200802222B (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA200802411B (en) * | 2005-09-15 | 2009-09-30 | Orchid Res Lab Ltd | Novel pyrimidine carboxamides |
| DOP2006000210A (es) | 2005-10-04 | 2007-06-15 | Aventis Pharma Inc | Compuestos de pirimidina amida como inhibidores de pgds |
| KR20080109918A (ko) | 2006-04-11 | 2008-12-17 | 버텍스 파마슈티칼스 인코포레이티드 | 전압 개폐 나트륨 채널의 억제제로서 유용한 조성물 |
| CA2672373C (en) | 2006-12-19 | 2011-08-30 | Pfizer Products Inc. | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
| JP2010519328A (ja) * | 2007-02-26 | 2010-06-03 | ファイザー・プロダクツ・インク | Ｈ−ｐｇｄｓの阻害剤としてのニコチンアミド誘導体およびプロスタグランジンｄ２が媒介する疾患の治療のためのそれらの使用 |
| JP5718053B2 (ja) | 2007-08-27 | 2015-05-13 | ヘリコン・セラピューティクス・インコーポレーテッド | 治療用イソオキサゾール化合物 |
| MX2010003865A (es) | 2007-10-11 | 2010-06-01 | Vertex Pharma | Aril amidas utiles como inhibidores de canales de sodio dependientes de voltaje. |
| NZ584475A (en) * | 2007-10-11 | 2012-07-27 | Vertex Pharma | Heteroaryl amides useful as inhibitors of voltage-gated sodium channels |
| RU2010118481A (ru) | 2007-10-11 | 2011-11-20 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Амиды, применимые в качестве ингибиторов потенциалзависимых натриевых каналов |
| US8153651B2 (en) * | 2007-11-13 | 2012-04-10 | Evotec Ag | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
| US8188280B2 (en) * | 2008-02-06 | 2012-05-29 | Msd K.K. | 3-substituted sulfonyl piperidine derivative |
| EP2286221A4 (en) * | 2008-05-13 | 2011-07-06 | Cayman Chem Co | METHOD FOR TESTING COMPOUNDS OR MEANS FOR THEIR POSSIBILITY TO DISPLACE STRONG LIGANDS OF THE HEMATOPOIETIC PROSTAGLANDIN D-SYNTHASE |
| TW201010997A (en) | 2008-06-18 | 2010-03-16 | Pfizer Ltd | Nicotinamide derivatives |
| US20110306597A1 (en) | 2008-06-18 | 2011-12-15 | James Michael Crawforth | Nicotinamide Derivatives |
| US8536185B2 (en) | 2008-09-22 | 2013-09-17 | Cayman Chemical Company, Incorporated | Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases |
| KR101252335B1 (ko) | 2009-07-16 | 2013-04-08 | (주)아모레퍼시픽 | 피부 노화 방지용 조성물 |
| WO2010056044A2 (ko) * | 2008-11-11 | 2010-05-20 | (주)아모레퍼시픽 | 바닐로이드 수용체 길항제로 작용하는 신규 화합물, 이의 이성질체 또는 이의 약제학적으로 허용 가능한 염 및 이를 포함하는 약학 조성물 |
| KR101367057B1 (ko) | 2009-03-17 | 2014-02-25 | (주)아모레퍼시픽 | 피부 자극 완화용 조성물 |
| JP5111657B2 (ja) | 2009-03-09 | 2013-01-09 | 大鵬薬品工業株式会社 | プロスタグランジンｄ合成酵素を阻害するピペラジン化合物 |
| MX2012003021A (es) * | 2009-10-08 | 2012-04-10 | Sanofi Sa | Derivados de feniloxadiazol como agentes inhibidores de las pgds. |
| AU2011208139B2 (en) | 2010-01-22 | 2014-10-23 | Taiho Pharmaceutical Co., Ltd. | Piperazine compound having a PGDS inhibitory effect |
| US9320723B2 (en) * | 2010-05-03 | 2016-04-26 | University Of Rochester | Methods of treating thyroid eye disease |
| WO2011150457A2 (en) * | 2010-06-01 | 2011-12-08 | The University Of Queensland | Haematopoietic-prostaglandin d2 synthase inhibitors |
| AU2011299904A1 (en) | 2010-09-07 | 2013-05-02 | Taiho Pharmaceutical Co., Ltd. | Prostaglandin D synthase inhibitory piperidine compounds |
| KR101271223B1 (ko) | 2011-01-27 | 2013-06-07 | 한국과학기술연구원 | 아미노피리미딘 유도체 및 이를 포함하는 세포외 신호조절 키나제의 제해제 |
| CN104159587A (zh) | 2012-01-06 | 2014-11-19 | 南佛罗里达大学 | 组合物、使用方法、以及治疗方法 |
| RU2655914C9 (ru) * | 2012-08-24 | 2018-07-24 | Саншайн Лейк Фарма Ко., Лтд. | Соединения дигидропиримидина и их применение в фармацевтических препаратах |
| WO2017103851A1 (en) | 2015-12-17 | 2017-06-22 | Astex Therapeutics Limited | Quinoline-3-carboxamides as h-pgds inhibitors |
| WO2017160832A1 (en) * | 2016-03-14 | 2017-09-21 | Emory University | Amide-sulfamide derivatives, compositions, and uses related to cxcr4 inhibition |
| JOP20190072A1 (ar) * | 2016-10-13 | 2019-04-07 | Glaxosmithkline Ip Dev Ltd | مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم |
| US11149035B2 (en) | 2017-06-13 | 2021-10-19 | Glaxosmithkline Intellectual Property Dfvelopment Limited | Chemical compounds as H—PGDS inhibitors |
| EP3700521B1 (en) * | 2017-10-29 | 2024-06-12 | China Medical University | Use of adam9 inhibitor compound and composition including adam9 inhibitor compound |
| CN111479814A (zh) | 2017-12-13 | 2020-07-31 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为h-pgds抑制剂的稠合的吡啶 |
| CA3093050A1 (en) * | 2018-03-23 | 2019-09-26 | Step Pharma S.A.S. | Aminopyrimidine derivatives as ctps1 inhibitors |
| WO2020095215A1 (en) | 2018-11-08 | 2020-05-14 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds |
| AU2021272972A1 (en) * | 2020-05-13 | 2022-12-08 | Chdi Foundation, Inc. | HTT modulators for treating Huntington's disease |
| EP4169575A4 (en) | 2020-06-19 | 2023-10-25 | Sato Pharmaceutical Co., Ltd. | Condensed ring compounds that inhibit h-pgds |
| EP4232425A4 (en) * | 2020-10-23 | 2024-07-24 | Nimbus Clotho, Inc. | Ctps1 inhibitors and uses thereof |
| CN113004208A (zh) * | 2021-03-08 | 2021-06-22 | 沈阳药科大学 | 一种抑制黄嘌呤氧化酶活性的化合物及制备方法和应用 |
| AU2022394333A1 (en) | 2021-11-17 | 2024-06-27 | Chdi Foundation, Inc. | HTT modulators for treating Huntington’s disease |
| KR20240121786A (ko) | 2021-12-17 | 2024-08-09 | 사토 세이야쿠 가부시키가이샤 | H－pgds를 저해하는 아자인돌 유도체 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003112985A (ja) | 2001-10-01 | 2003-04-18 | Nre Happiness Kk | 食品残渣肥、飼料原料化システムおよびそれに使用する破砕貯留処理ユニット並びに乾燥冷却処理ユニット |
| WO2004072069A1 (en) | 2003-02-14 | 2004-08-26 | Glaxo Group Limited | Carboxamide derivatives |
| WO2005032493A2 (en) | 2003-10-07 | 2005-04-14 | Renovis, Inc. | Amide compounds as ion channel ligands and uses thereof |
| EP1553089A1 (en) * | 2002-07-30 | 2005-07-13 | Banyu Pharmaceutical Co., Ltd. | Antagonist of melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2934543A1 (de) * | 1979-08-27 | 1981-04-02 | Basf Ag, 6700 Ludwigshafen | Substituierte n-benzoylanthranilsaeurederivate und deren anydroverbindungen, verfahren zu ihrer herstellung und ihre verwendung als herbizide |
| JPH03112985A (ja) * | 1989-09-28 | 1991-05-14 | Morishita Pharmaceut Co Ltd | Ｎ―（１ｈ―テトラゾール―５―イル）―２―フェニル―５―ピリミジンカルボキシアミド類及びその合成用中間体 |
| GB9405347D0 (en) * | 1994-03-18 | 1994-05-04 | Agrevo Uk Ltd | Fungicides |
| JP2000226372A (ja) * | 1999-02-01 | 2000-08-15 | Nippon Soda Co Ltd | アミド化合物、その製造方法及び農園芸用殺虫剤 |
| JP2002003370A (ja) * | 1999-09-20 | 2002-01-09 | Takeda Chem Ind Ltd | メラニン凝集ホルモン拮抗剤 |
| WO2001021577A2 (en) * | 1999-09-20 | 2001-03-29 | Takeda Chemical Industries, Ltd. | Melanin concentrating hormone antagonist |
| MY138097A (en) * | 2000-03-22 | 2009-04-30 | Du Pont | Insecticidal anthranilamides |
| WO2004011430A1 (ja) * | 2002-07-25 | 2004-02-05 | Yamanouchi Pharmaceutical Co., Ltd. | ナトリウムチャネル阻害剤 |
| DE60303238T2 (de) * | 2003-04-25 | 2006-09-14 | Actimis Pharmaceuticals, Inc., La Jolla | Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten |
| EP1737414A2 (en) * | 2004-01-23 | 2007-01-03 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments of inflammatory and neuropatic pain |
| DOP2006000210A (es) | 2005-10-04 | 2007-06-15 | Aventis Pharma Inc | Compuestos de pirimidina amida como inhibidores de pgds |
-
2006
- 2006-10-03 DO DO2006000210A patent/DOP2006000210A/es unknown
- 2006-10-03 PE PE2010000532A patent/PE20110118A1/es not_active Application Discontinuation
- 2006-10-03 AR ARP060104348A patent/AR056871A1/es unknown
- 2006-10-03 PE PE2006001202A patent/PE20070589A1/es not_active Application Discontinuation
- 2006-10-04 AU AU2006299428A patent/AU2006299428B2/en not_active Ceased
- 2006-10-04 WO PCT/US2006/038841 patent/WO2007041634A1/en not_active Ceased
- 2006-10-04 EP EP06816247.8A patent/EP1937652B1/en active Active
- 2006-10-04 SG SG201007241-1A patent/SG166121A1/en unknown
- 2006-10-04 ES ES06816247.8T patent/ES2514471T3/es active Active
- 2006-10-04 UY UY29840A patent/UY29840A1/es unknown
- 2006-10-04 CN CN200910138053.9A patent/CN101538246B/zh active Active
- 2006-10-04 UA UAA200805322A patent/UA93213C2/ru unknown
- 2006-10-04 MY MYPI20080754 patent/MY151172A/en unknown
- 2006-10-04 KR KR1020087008306A patent/KR101457966B1/ko not_active Expired - Fee Related
- 2006-10-04 TW TW095136806A patent/TWI415839B/zh not_active IP Right Cessation
- 2006-10-04 RU RU2008117170/04A patent/RU2420519C2/ru not_active IP Right Cessation
- 2006-10-04 BR BRPI0616815-9A patent/BRPI0616815A2/pt not_active IP Right Cessation
- 2006-10-04 NZ NZ567208A patent/NZ567208A/en not_active IP Right Cessation
- 2006-10-04 CN CNA2006800365786A patent/CN101282943A/zh active Pending
- 2006-10-04 CA CA2624749A patent/CA2624749C/en not_active Expired - Fee Related
- 2006-10-04 JP JP2008534664A patent/JP5452925B2/ja active Active
-
2008
- 2008-03-07 TN TNP2008000104A patent/TNSN08104A1/en unknown
- 2008-03-10 ZA ZA200802222A patent/ZA200802222B/xx unknown
- 2008-03-24 IL IL190411A patent/IL190411A/en not_active IP Right Cessation
- 2008-03-26 CR CR9832A patent/CR9832A/es not_active Application Discontinuation
- 2008-04-02 EC EC2008008335A patent/ECSP088335A/es unknown
- 2008-04-04 US US12/062,641 patent/US8202863B2/en active Active
- 2008-04-28 NO NO20082000A patent/NO20082000L/no not_active Application Discontinuation
- 2008-05-02 MA MA30891A patent/MA29925B1/fr unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003112985A (ja) | 2001-10-01 | 2003-04-18 | Nre Happiness Kk | 食品残渣肥、飼料原料化システムおよびそれに使用する破砕貯留処理ユニット並びに乾燥冷却処理ユニット |
| EP1553089A1 (en) * | 2002-07-30 | 2005-07-13 | Banyu Pharmaceutical Co., Ltd. | Antagonist of melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient |
| WO2004072069A1 (en) | 2003-02-14 | 2004-08-26 | Glaxo Group Limited | Carboxamide derivatives |
| WO2005032493A2 (en) | 2003-10-07 | 2005-04-14 | Renovis, Inc. | Amide compounds as ion channel ligands and uses thereof |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101457966B1 (ko) | Ｐｇｄｓ 억제제로서 피리미딘 아미드 화합물 | |
| JP4440642B2 (ja) | ピリミジンＡ２ｂ選択的アンタゴニスト化合物、それらの合成、及び使用 | |
| RU2417990C2 (ru) | 2,6-замещенные-4-монозамещенный амино-пиримидины как антагонисты рецептора простагландина d2 | |
| US7998978B2 (en) | Substituted 2-amino-fused heterocyclic compounds | |
| RU2464262C2 (ru) | Пиримидингидразидные соединения как ингибиторы pgds | |
| TWI642670B (zh) | Ｐｉ３ｋ-德爾塔抑制劑以及其應用和生產方法 | |
| US20090042928A1 (en) | Modulators of muscarinic receptors | |
| TWI652263B (zh) | Ｒｏｒｃ２抑制劑及其使用方法 | |
| US8163742B2 (en) | Di-amino-substituted heterocyclic compounds and methods of use | |
| CN101528744A (zh) | 用于调节c-kit和pdgfr受体的组合物和方法 | |
| JP2004520324A (ja) | カルバゾール誘導体およびニューロペプチドｙ５受容体リガンドとしてのそれらの使用 | |
| KR20120002581A (ko) | 피리미딘 화합물 | |
| CN103534240A (zh) | 选择性fak抑制剂 | |
| CN1414965A (zh) | 调整内皮肽活性的磺酰胺及其衍生物 | |
| CN102395584A (zh) | 用于代谢疾病治疗的化合物 | |
| WO2018222917A1 (en) | Ire1 small molecule inhibitors | |
| US20070072901A1 (en) | 1-Amino-isoquinoline derivatives for the treatment of diseases associated with inappropriate alk5 | |
| WO2017167150A1 (zh) | 一种3-氟吡啶杂环化合物及其应用 | |
| HK1136162A (en) | Pyrimidine amide compounds as pgds inhibitors | |
| HK1139413A (en) | Pyrimidine hydrazide compounds as pgds inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-3-3-R10-R17-oth-X000 |
|
| A201 | Request for examination | ||
| AMND | Amendment | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-3-3-R10-R17-oth-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| AMND | Amendment | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| AMND | Amendment | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PJ0201 | Trial against decision of rejection |
St.27 status event code: A-3-3-V10-V11-apl-PJ0201 |
|
| PB0901 | Examination by re-examination before a trial |
St.27 status event code: A-6-3-E10-E12-rex-PB0901 |
|
| B701 | Decision to grant | ||
| PB0701 | Decision of registration after re-examination before a trial |
St.27 status event code: A-3-4-F10-F13-rex-PB0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-4-4-P10-P22-nap-X000 |
|
| LAPS | Lapse due to unpaid annual fee | ||
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20171030 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20171030 |